Page 232 - 2019_03-Haematologica-web

638
haematologica | 2019; 104(3)
E.M. Dauber et al. References
1. Daniels G. Human blood groups. 3rd ed. Oxford: Wiley-Blackwell, 2013.
2. Flegel WA. Molecular genetics and clinical applications for RH. Transfus Apher Sci. 2011;44(1):81-91.
3. Drexler C, Wagner T. Blood group chimerism. Curr Opin Hematol. 2006; 13(6):484-489.
4. Körmöczi GF, Dauber EM, Haas OA, et al. Mosaicism due to myeloid lineage restricted loss of heterozygosity as cause of sponta- neous Rh phenotype splitting. Blood. 2007;110(6):2148-2157.
5. Tovey GH, Lockyer JW, Tierney RB. Changes in Rh grouping reactions in a case of leukaemia. Vox Sang. 1961;6(5):628-631.
6. Orlando N, Putzulu R, Nuzzolo ER, et al. Primary myelofibrosis: when the clone manifests with Rh phenotype splitting. Ann Hematol. 2014;93(6):1077-1078.
7. Majsky A. Some cases of leukaemia with modifications of the D(Rho)-receptor. Neoplasma. 1967;14(4):335-344.
8. Bracey AW, McGinniss MH, Levine RM, Whang-Peng J. Rh mosaicism and aberrant MNSs antigen expression in a patient with chronic myelogenous leukemia. Am J Clin Pathol. 1983;79(3):397-401.
9. Mertens G, Gielis M, Muylle L, de Raedt S. Loss of D and C expression in chronic myelomonocytic leukemia. Transfusion. 1997;37(8):880-881.
10. van Bockstaele DR, Berneman ZN, Muylle L, Cole-Dergent J, Peetermans ME. Flow cytometric analysis of erythrocytic D anti- gen density profile. Vox Sang. 1986; 51(1):40-46.
11. Winters JL, Howard DS. Red blood cell anti- gen changes in malignancy: case report and review. Immunohematol. 2001;17(1):1-9.
12. Cooper B, Tishler PV, Atkins L, Breg WR. Loss of Rh antigen associated with acquired Rh antibodies and a chromosome transloca- tion in a patient with myeloid metaplasia. Blood. 1979;54(3):642-647.
13. Mohandas K, Najfield V, Gilbert H, Azar P, Skerrett D. Loss and reappearance of Rho(D) antigen on the red blood cells of an individual with acute myelogenous leukemia. Immunohematol. 1994;10(4): 134-135.
14. Callender ST, Kay HE, Lawler SD, Millard RE, Sanger R, Tippett PA. Two populations of Rh groups together with chromosomally abnormal cell lines in the bone marrow. Br Med J. 1971;1(5741):131-133.
15. Habibi B, Lopez M, Salmon C. Two new cases of Rh mosaicism - selective study of red cell populations. Vox Sang. 1974; 27(3):232-242.
16. Northoff H, Goldmann SF, Lattke H,
Transfus Med Hemother. 2014; 41(6):446- antigens lacking other signs of chimerism or 451.
Steinbach P. A patient, mosaic for Rh and Fy
chromosomal disorder. Vox Sang.
1984;47(2):164-169.
17. Salaru NN, Lay WH. Rh blood group
mosaicism in a healthy elderly woman. Vox
Sang. 1985;48(6):362-365.
18. Wagner FF, Frohmajer A, Flegel WA. RHD
positive haplotypes in D negative
Europeans. BMC Genet. 2001;2:10.
19. Cherif-Zahar B, Bony V, Steffensen R, et al. Shift from Rh-positive to Rh-negative phe- notype caused by a somatic mutation with- in the RHD gene in a patient with chronic myelocytic leukaemia. Br J Haematol.
1998;102(5):1263-1270.
20. Marsh WL, Chaganti RS, Gardner FH,
Mayer K, Nowell PC, German J. Mapping human autosomes: evidence supporting assignment of rhesus to the short arm of chromosome No. 1. Science. 1974; 183(4128):966-968.
21. Murdock A, Assip D, Hue-Roye K, et al. RHD deletion in a patient with chronic myeloid leukemia. Immunohematology. 2008;24(4):160-164.
22. Körmöczi GF, Legler TJ, Daniels GL, et al. Molecular and serologic characterization of DWI, a novel "high-grade" partial D. Transfusion. 2004;44(4):575-580.
23. Fritsch G, Witt V, Dubovsky J, et al. Flow cytometric monitoring of hematopoietic reconstitution in myeloablated patients fol- lowing allogeneic transplantation. Cytotherapy. 1999;1(4):295-309.
24. Walsh PS, Metzger DA, Higuchi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques. 1991;10(4):506- 513.
25. Körmöczi GF, Förstemann E, Gabriel C, Mayr WR, Schönitzer D, Gassner C. Novel weak D types 31 and 32: adsorption-elu- tion-supported D antigen analysis and com- parison to prevalent weak D types. Transfusion. 2005;45(10):1574-1580.
26. Legler TJ, Lynen R, Maas JH, et al. Prediction of fetal Rh D and Rh CcEe phenotype from maternal plasma with real-time polymerase chain reaction. Transfus Apher Sci. 2002;27(3):217-223.
27. Tippett P. Blood group chimeras. A review. Vox Sang. 1983;44(6):333-359.
28. Evers D, Middelburg RA, de Haas M, et al. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immuno- genicity: a cohort study. Lancet Haematol. 2016;3(6):e284-292.
29. Rees DC, Robinson S, Howard J. How I manage red cell transfusions in patients with sickle cell disease. Br J Haematol. 2018;180(4):607-617.
30. Körmöczi GF, Mayr WR. Responder individ- uality in red blood cell alloimmunization.
31. Papay P, Hackner K, Vogelsang H, et al. High risk of transfusion-induced alloimmuniza- tion of patients with inflammatory bowel disease. Am J Med. 2012; 125(7):717.e1-8.
32. Delaney M, Wikman A, van de Watering L, et al. Blood Group Antigen Matching Influence on Gestational Outcomes (AMIGO) study. Transfusion. 2017;57(3): 525-532.
33. Machiela MJ, Chanock SJ. The ageing genome, clonal mosaicism and chronic dis- ease. Curr Opin Genet Dev. 2017;42(2):8-13.
34. Forsberg LA, Gisselsson D, Dumanski JP. Mosaicism in health and disease - clones picking up speed. Nat Rev Genet. 2017; 18(2):128-142.
35. Montemayor-Garcia C, Coward R, Albitar M, et al. Acquired RhD mosaicism identifies fibrotic transformation of thrombopoietin receptor-mutated essential thrombo- cythemia. Transfusion. 2017;57(9):2136- 2139.
36. Chow S, Pendergrast J, Ochoa-Garay G, et al. Mixed fields on RhD typing as an indica- tion of loss of heterozygosity on chromo- some 1p in acute myeloid leukemia. Leuk Lymphoma. 2015;56(7):2196-2199.
37. O'Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignan- cies. Blood. 2010;115(14):2731-2739.
38. Rumi E, Pietra D, Guglielmelli P, et al. Acquired copy-neutral loss of heterozygosi- ty of chromosome 1p as a molecular event associated with marrow fibrosis in MPL- mutated myeloproliferative neoplasms. Blood. 2013;121(21):4388-4395.
39. Zhou CZ, Qiu GQ, Zhang F, He L, Peng ZH. Loss of heterozygosity on chromosome 1 in sporadic colorectal carcinoma. World J Gastroenterol. 2004;10(10):1431-1435.
40. White PS, Maris JM, Beltinger C, et al. A region of consistent deletion in neuroblas- toma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci USA. 1995; 92(12):5520-5524.
41. Nomoto S, Haruki N, Tatematsu Y, et al. Frequent allelic imbalance suggests involve- ment of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers. Genes Chromosomes Cancer. 2000;28(3):342-346.
42. Yeh SH, Chen PJ, Chen HL, Lai MY, Wang CC, Chen DS. Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas. Cancer Res. 1994;54(15):4188-4192.
43. Gronseth CM, McElhone SE, Storer BE, et al. Prognostic significance of acquired copy- neutral loss of heterozygosity in acute myeloid leukemia. Cancer. 2015; 121(17): 2900-2908.